PMID- 25057343
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140724
LR  - 20211021
IS  - 2045-1253 (Print)
IS  - 2045-1261 (Electronic)
IS  - 2045-1253 (Linking)
VI  - 4
IP  - 3
DP  - 2014 Jun
TI  - Add-on clinical effects of simvastatin and ondansetron in patients with 
      schizophrenia stabilized on antipsychotic treatment: pilot study.
PG  - 110-6
LID - 10.1177/2045125313511487 [doi]
AB  - OBJECTIVES: There is some evidence that anti-inflammatory treatment may have 
      beneficial effects in schizophrenia and major depression. Statins are 
      cholesterol-lowering agents but have been found to be anti-inflammatory and also 
      decrease C-reactive protein (CRP). Ondansetron is a serotonin (5-HT3) receptor 
      antagonist widely used to prevent nausea and vomiting in patients receiving 
      chemotherapy for cancer. Small studies have suggested that adjunctive ondansetron 
      is efficacious against schizophrenia symptoms. We carried out a feasibility study 
      in schizophrenia patients (within 5 years of first diagnosis) to explore the 
      adjunctive use of simvastatin and ondansetron on positive, negative and general 
      psychopathology. METHODS: This was a 12-week rater-blind placebo-controlled 
      study. A total of 36 patients with DSM-IV diagnosis of schizophrenia were 
      recruited, 12 in each arm. Patients were assessed at baseline and at 12 weeks 
      using Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression 
      (CGI) scale, Global Assessment of Functioning (GAF) and Abnormal Involuntary 
      Movement Scale (AIMS). RESULTS: Both simvastatin and ondansetron provide some 
      evidence of a reduction in symptoms compared with treatment as usual (TAU) on 
      PANSS total score, although this was not statistically significant. In the 
      secondary analyses, no significant differences were seen on CGI, GAF and AIMS. 
      CONCLUSIONS: Anti-inflammatory treatments have been shown to have some beneficial 
      effects in schizophrenia. Both simvastatin and ondansetron provide some evidence 
      of a reduction in symptoms compared with TAU. This study has led to a larger 
      Stanley Medical Research Institute (SMRI)-funded, double-blind, randomized 
      control trial.
FAU - Chaudhry, Imran B
AU  - Chaudhry IB
AD  - University of Manchester, Manchester, UK.
FAU - Husain, Nusrat
AU  - Husain N
AD  - University of Manchester, Manchester, UK.
FAU - Drake, Richard
AU  - Drake R
AD  - University of Manchester, Manchester, UK.
FAU - Dunn, Graham
AU  - Dunn G
AD  - University of Manchester, Manchester, UK.
FAU - Husain, M Omair
AU  - Husain MO
AD  - Southwest London and St George's NHS Trust, London, UK.
FAU - Kazmi, Ajmal
AU  - Kazmi A
AD  - Pakistan Institute of Learning & Living, Karachi, Pakistan.
FAU - Hamirani, Munir M
AU  - Hamirani MM
AD  - Abbassi Shaheed Hospital Karachi, Karachi, Pakistan.
FAU - Rahman, Raza
AU  - Rahman R
AD  - Dow University of Health Sciences, Karachi, Pakistan.
FAU - Stirling, John
AU  - Stirling J
AD  - University of Manchester, Manchester, UK.
FAU - Deakin, William
AU  - Deakin W
AD  - University of Manchester, Manchester, UK.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ther Adv Psychopharmacol
JT  - Therapeutic advances in psychopharmacology
JID - 101555693
PMC - PMC4107703
OTO - NOTNLM
OT  - Psychosis
OT  - anti-inflammatory
OT  - ondansetron
OT  - schizophrenia
OT  - simvastatin
COIS- Conflict of interest statement: The author declares that there is no conflict of 
      interest.
EDAT- 2014/07/25 06:00
MHDA- 2014/07/25 06:01
PMCR- 2014/06/01
CRDT- 2014/07/25 06:00
PHST- 2014/07/25 06:00 [entrez]
PHST- 2014/07/25 06:00 [pubmed]
PHST- 2014/07/25 06:01 [medline]
PHST- 2014/06/01 00:00 [pmc-release]
AID - 10.1177_2045125313511487 [pii]
AID - 10.1177/2045125313511487 [doi]
PST - ppublish
SO  - Ther Adv Psychopharmacol. 2014 Jun;4(3):110-6. doi: 10.1177/2045125313511487.